Abstract:Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal A(1-42) expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed <1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 7286% (P<10(-6)). In worms expressing A(1-42), knockdown of cram-1 reduced -amyloid 60% (P<0.002) and slowed age-dependent paralysis >30% (P<10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Mechanisms and pathology of protein misfolding and aggregation

Molecular determinants of protein pathogenicity at the single-aggregate level

Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception

Protein aggregation and its affecting mechanisms in neurodegenerative diseases

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Fluctuations in protein aggregation: Design of preclinical screening for early diagnosis of neurodegenerative disease

Unraveling the Molecular Jam: How Crowding Shapes Protein Aggregation in Neurodegenerative Disorders

Protein aggregation: An overview

Transcellular transmission and molecular heterogeneity of aggregation-prone proteins in neurodegenerative diseases

Modulation of α-synuclein aggregation amid diverse environmental perturbation

Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases

Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases

Modulation of -Synuclein Aggregation Amid Diverse Environmental Perturbation

Molecular insights into aggrephagy: Their cellular functions in the context of neurodegenerative diseases

Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways

Protein Aggregation: Opposing Effects of Chaperones and Crowding

Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases

A network aggregation model for the dynamics and treatment of neurodegenerative diseases at the brain scale